[Commentary to the article: ONTARGET Investigators, Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59].
Dominiak
Marcin
M
II Katedra i Klinika Kardiologii, Uniwersytet Medyczny, Łódź.